LB Pharmaceuticals Taps 25-Year Biotech Vet to Drive LB-102 Phase 2 and 3 Trials
LBRX•LB Pharmaceuticals named Christopher Zergebel as Senior Vice President, Clinical Operations; he brings more than 25 years of global development operations experience overseeing clinical operations, data management and project and portfolio management. His appointment coincides with LB-102’s Phase 3 schizophrenia trial and Phase 2 bipolar depression study underway, and a Phase 2 adjunctive major depressive disorder trial scheduled to start early next year to drive key pipeline progress.
1. Executive Appointment and Role
LB Pharmaceuticals has appointed Christopher Zergebel as Senior Vice President of Clinical Operations. In this role, Zergebel will lead clinical operations, data management, and project and portfolio management functions to support the company’s late-stage pipeline.
2. Clinical Pipeline Oversight
Zergebel joins as LB-102 advances through a pivotal Phase 3 schizophrenia trial and an ongoing Phase 2 trial in bipolar depression. The company also plans to initiate a Phase 2 adjunctive major depressive disorder study early next year under his operational leadership.
3. Industry Experience and Leadership
With over 25 years in biotechnology, Zergebel previously served as Vice President of Development Operations at Cellectis Biologics, overseeing global clinical strategy from early-stage research through post-approval trials. He has built and optimized cross-functional teams and managed R&D budgets to support regulatory submissions and approvals.
4. Strategic Implications for LB-102 Development
His appointment is intended to bolster execution efficiency and strategic alignment as LB Pharmaceuticals scales its clinical programs. Enhanced operational leadership is expected to accelerate milestone delivery and reinforce the company’s positioning in neuropsychiatric therapeutics.
